Effectiveness and safety of abacavir, lamivudine, and zidovudine in antiretroviral therapy-naive HIV-infected patients: Results from a large multicenter observational cohort

Journal of Acquired Immune Deficiency Syndromes

Volumn 41, Issue 2, 2006, Pages 154-159

  Berenguer, Juan ^a   Pérez Elías, María Jesús ^b   Bellón, José María ^a   Knobel, Hernando ^c   Rivas González, Pablo ^d   Gatell, José María ^e   Miguélez, Máximo ^f   Hernández Quero, José ^g   Flores, Juan ^h   Soriano, Vicente ⁱ   Santos, Ignacio ^j   Podzamczer, Daniel ^k   Sala, Monserrat ^l   Camba, Manuel ^m   Resino, Salvador ^a  

^a HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^b HOSPITAL RAMÓN Y CAJAL   (Spain)

^c HOSPITAL DEL MAR   (Spain)

^d Hospital UniversitarioFundación Jiménez Díaz   (Spain)

^e HOSPITAL CLÍNIC   (Spain)

^f HOSPITAL UNIVERSITARIO NUESTRA SEÑORA DE CANDELARIA   (Spain)

^g HOSPITAL UNIVERSITARIO SAN CECILIO   (Spain)

^h HOSPITAL ARNAU DE VILANOVA   (Spain)

ⁱ HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^j HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

^k HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^l Department of Internal Medicine   (Spain)

^m POVISA   (Spain)

more..

Author keywords

Abacavir adverse effects therapeutic use; Abacavir hypersensitivity reaction; Combination; Dideoxynucleosides adverse effects therapeutic use; Drug therapy; Follow up studies; HIV infections *drug therapy; Lamivudine therapeutic use

Indexed keywords

ABACAVIR; ABACAVIR PLUS LAMIVUDINE PLUS ZIDOVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; METHADONE; 2',3' DIDEOXYNUCLEOSIDE DERIVATIVE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; LAMIVUDINE; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; BLOOD TOXICITY; CD4 LYMPHOCYTE COUNT; CLINICAL TRIAL; COHORT ANALYSIS; CYTOMEGALOVIRUS; DEMENTIA; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; FEVER; FOLLOW UP; GASTROINTESTINAL TOXICITY; HEPATITIS B; HEPATITIS C; HIGH RISK POPULATION; HODGKIN DISEASE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERSENSITIVITY REACTION; KAPOSI SARCOMA; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALAISE; MALE; MIGRAINE; MITOCHONDRIAL TOXICITY; MORTALITY; MULTICENTER STUDY; MYCOBACTERIUM AVIUM; MYOPATHY; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; RASH; REBOUND; RETINITIS; RETROSPECTIVE STUDY; SPAIN; STATISTICAL ANALYSIS; SUPERINFECTION; TREATMENT FAILURE; TUBERCULOSIS; VIRUS LOAD; DRUG COMBINATION; HYPERSENSITIVITY;

ADULT; ANTI-HIV AGENTS; COHORT STUDIES; DIDEOXYNUCLEOSIDES; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; HYPERSENSITIVITY; LAMIVUDINE; MALE; PATIENT COMPLIANCE; RETROSPECTIVE STUDIES; SPAIN; TREATMENT FAILURE; ZIDOVUDINE;

EID: 33645292085     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.qai.0000194231.08207.8a     Document Type: Article

References (12)

1. Staszewski S, Keiser P, Montaner J, et al. Abacavir-lamivudine-zidovudine vs indinavir-lamivudine-zidovudine in antiretroviral-naive HIV-infected adults: a randomized equivalence trial. JAMA. 2001;285:1155-1163.
2. Vibhagool A, Cahn P, Schechter M, et al. Triple nucleoside treatment with abacavir plus the lamivudine/zidovudine combination tablet (COM) compared to indinavir/COM in antiretroviral therapy-naive adults: results of a 48-week open-label, equivalence trial (CNA 3014). Curr Med Res Opin. 2004;20:1103-1114.
3. Gulick RM, Ribaudo HJ, Shikuma CM, et al. Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection. N Engl J Med. 2004;350:1850-1861.
4. Yeni PG, Hammer SM, Hirsch MS, et al. Treatment for adult HIV infection: 2004 recommendations of the International AIDS Society-USA Panel. JAMA. 2004;292:251-265.
5. Schulz KF, Chalmers I, Hayes RJ, et al. Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA. 1995;273:408-412.
6. Hewitt RG. Abacavir hypersensitivity reaction. Clin Infect Dis. 2002;34:1137-1142.
7. Rubio R, Berenguer J, Miro JM, et al. Recommendations of the Spanish AIDS Study Group (GESIDA) and the National Aids Plan (PNS) for antiretroviral treatment in adult patients with human immunodeficiency virus infection in 2002. Enferm Infecc Microbiol Clin. 2002;20:244-303.
8. Knobel H, Alonso J, Casado JL, et al. Validation of a simplified medication adherence questionnaire in a large cohort of HIV-infected patients: the GEEMA Study. AIDS. 2002;16:605-613.
9. Matheron S, Descamps D, Boue F, et al. Triple nucleoside combination zidovudine/lamivudine/abacavir versus zidovudine/lamivudine/nelfinavir as first-line therapy in HIV-1-infected adults: a randomized trial. Antivir Ther. 2003;8:163-171.
10. Phillips AN, Grabar S, Tassie JM, et al. Use of observational databases to evaluate the effectiveness of antiretroviral therapy for HIV infection: comparison of cohort studies with randomized trials. EuroSIDA, the French Hospital Database on HIV and the Swiss HIV Cohort Study Groups. AIDS. 1999;13:2075-2082.
11. Egger M, May M, Chene G, et al. Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet. 2002;360:119-129.
12. Bartlett JA, DeMasi R, Quinn J, et al. Overview of the effectiveness of triple combination therapy in antiretroviral-naive HIV-1 infected adults. AIDS. 2001;15:1369-1377.